It became the first ALK inhibitor to be approved by the Food and Drug Administration (FDA) in 2011 for standard first-line therapy in ALK-positive NSCLC, which accounts for approximately 2–7% of patients diagnosed with NSCLC [6]. Here, ALK is linked to non-small cell lung carcinoma.